NCT00348725已完成3 期
An Open Label, Parallel-Arm, Multicenter Trial Assessing the Acceptability of 4 Dosages of a New Fixed Dose Combination of Fenofibrate and Metformin in Patients With Type 2 Diabetes and Dyslipidemia
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 69
- 试验地点
- 35
- 主要终点
- Quotation by Visual Numeric Rating Scale before and after 4-week treatment
研究概览
简要总结
The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with type 2 diabetes mellitus and dyslipidemia.
排除标准
- •Type 1 diabetes, uncontrolled type 2 diabetes, - HbA1c ≥ 10 % - Fasting plasma glucose > 300 mg/dL - Triglycerides > 500 mg/dL
结局指标
主要结局
Quotation by Visual Numeric Rating Scale before and after 4-week treatment
次要结局
- Assessment of safety by reporting of Adverse Events
研究者
研究点 (35)
Loading locations...
相似试验
已完成
3 期
Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and DyslipidemiaDiabetes Mellitus, Type 2DyslipidemiaNCT00490178Solvay Pharmaceuticals29
已完成
4 期
Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic FailureHIV InfectionNCT00038506ViiV Healthcare100
已完成
4 期
Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)Chronic Rhinosinusitis With Nasal PolypsNCT05049122Sanofi25
已完成
不适用
Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy ParticipantsImmunity DisordersNCT05242718Immunoflex Therapeutics Inc.32
招募中
4 期
Open-label Study to Evaluate Metreleptin in Patients With Partial LipodystrophyPartial LipodystrophyNCT06484868Amryt Pharma12